1. Basic Product Identification
Name: Delamanid
Brand: Deltyba
Class: Antitubercular agent (nitro-dihydro-imidazooxazole derivative)
ATC Code: J04AK06
Molecular Formula: C₂₆H₂₅F₃N₄O₆
Molecular Weight: 534.5 g/mol
Appearance: White to pale yellow crystalline powder
Solubility: Very low water solubility, soluble in organic solvents
Key Feature: New-generation drug for multidrug-resistant TB (MDR-TB)
2. Therapeutic Knowledge
Indication:
Multidrug-resistant tuberculosis (MDR-TB)
Extensively drug-resistant TB (XDR-TB) (in combination therapy)
Therapeutic class:
Mycobacterial cell wall inhibitor
Clinical role:
Used as part of WHO-recommended combination regimens
3. Mechanism of Action (MOA)
Inhibits mycolic acid synthesis in Mycobacterium tuberculosis
Specifically blocks:
Methoxy-mycolic acid and keto-mycolic acid production
Leads to:
Disruption of bacterial cell wall
Loss of bacterial viability
???? Prodrug activated inside mycobacteria by deazaflavin-dependent nitroreductase (Ddn)
4. Pharmacokinetics (ADME)
Absorption
Oral administration
Food increases bioavailability significantly
Distribution
High protein binding (~99.5%)
Extensive tissue distribution (lungs important site)
Metabolism
Primarily hepatic via albumin-mediated and enzymatic pathways
No major CYP450 involvement
Excretion
Feces (major)
Urine (minor metabolites)
Half-life
~30–38 hours
5. Dosage & Albania Administration
Standard adult dosing
100 mg twice daily (with food)
Duration
Typically 6–24 months depending on TB regimen
Administration rules
Must be taken with meals
Always used in combination therapy (never monotherapy)
6. Formulation Knowledge
Dosage forms
Film-coated tablets (primary marketed form)
Key excipients:
Microcrystalline cellulose
Hypromellose
Lactose monohydrate
Crospovidone
Magnesium stearate
Key formulation challenges:
Poor solubility → requires dissolution enhancement
Controlled release not typically used but bioavailability optimization is critical
7. Raw Materials Knowledge
API: Delamanid (nitro-imidazooxazole compound)
Key intermediates:
Nitroimidazole precursors
Fluorinated aromatic intermediates
Critical concerns:
Control of nitro-group reactivity
Impurity formation during nitration steps
8. Manufacturing Process Knowledge
API synthesis (high-level)
Multi-step organic synthesis:
Construction of imidazooxazole core
Fluorination chemistry
Nitro functional group introduction
Purification via crystallization & chromatography
Formulation steps:
Micronization for dissolution improvement
Wet granulation or direct compression
Film coating for stability
Low humidity manufacturing environment required
9. Analytical & QC Knowledge
Key tests:
Assay (HPLC)
Related substances (critical for nitro compounds)
Dissolution testing (biorelevant media)
Residual solvents (GC)
Polymorphic form analysis (XRPD)
Content uniformity
Critical impurities:
Nitro-reduction byproducts
Fluorinated intermediates
Degradation products under light exposure
10. Regulatory Knowledge
Approved for MDR-TB by:
EMA (conditional approval)
WHO prequalified in TB programs
Regulatory classification:
Essential medicine in MDR-TB regimens
Requirements:
Strict combination therapy justification
Long-term safety data submission
Global TB program integration (STOP TB initiative alignment)
11. Storage & Stability
Store at 15–30°C
Protect from:
Moisture
Light
Stability concerns:
Photodegradation risk
Oxidation of nitro group under stress conditions
12. Packaging Knowledge
API:
Moisture-resistant double bags + fiber drum
Tablets:
Alu-Alu blister packs preferred
TB program packaging:
Multi-month therapy packs
Heat & humidity-resistant packaging required
13. Safety & Toxicology
Common adverse effects:
Nausea
Headache
Insomnia
Serious risks:
QT prolongation (important safety monitoring)
Special monitoring:
ECG monitoring required in combination regimens
Contraindications:
Severe cardiac arrhythmia risk patients
14. Market & Commercial Knowledge
High-need niche anti-TB market
Key competitors:
Bedaquiline (main comparator drug)
Market drivers:
Rising MDR/XDR-TB cases globally
WHO TB elimination programs
Market limitation:
Restricted access programs in many countries
15. Intellectual Property (IP)
Developed by Otsuka Pharmaceutical
Strong global patent protection historically
IP focus:
TB regimen combinations
Pediatric formulations (emerging)
Market still partially controlled via access programs
16. Environmental & EHS Knowledge
Anti-infective compound with low environmental persistence risk
Manufacturing concerns:
Nitro compound handling safety
Controlled waste incineration
EHS controls:
PPE for powder handling
Dust explosion prevention in micronization
17. Export Documentation Knowledge
COA (Certificate of Analysis)
GMP certificate
WHO prequalification documentation (if applicable)
Stability data (Zone IVb important for TB regions)
Clinical justification dossiers (TB program supply)
Pharmacovigilance commitment documentation
18. Business Development Knowledge
Strong global demand via public health systems
Key buyers:
Government TB programs
Global Fund / WHO procurement systems
Strategy:
Affordable generic TB drug supply
Partnerships with NGOs
Tender-based procurement model
High-volume but price-sensitive market
19. Advanced Technical Knowledge
Prodrug activation dependent on bacterial enzyme (Ddn)
Nitro group chemistry critical for activity
Lipophilicity affects lung tissue penetration
Synergy with bedaquiline and linezolid in MDR regimens
Resistance risk management essential in combination design
20. AI & Digital Knowledge (Modern Pharma)
AI applications:
TB resistance prediction modeling
Regimen optimization (multi-drug simulations)
Patient adherence analytics in TB programs
Digital QA:
Global TB supply chain tracking systems
Public health analytics:
Epidemiological forecasting of MDR-TB spread
21. Sales Team Product Knowledge Checklist
Sales teams must know:
Indication: MDR/XDR TB only
Always used in combination therapy
QT prolongation risk (critical safety point)
Importance of adherence (long treatment duration)
Difference vs bedaquiline
Objections:
“Why long therapy?” → TB eradication biology
“Side effects?” → monitored in national TB programs
22. Most Important Technical Documents
DMF (API dossier)
WHO prequalification dossier
Stability reports (ICH + tropical conditions)
Clinical trial summaries (MDR-TB studies)
Dissolution similarity studies
Impurity qualification reports
ECG safety monitoring guidelines
Process validation reports
Pharmacovigilance plan (TB program level)
23. Ultimate Pharma Product Mastery Summary
Delamanid is:
A next-generation anti-tuberculosis agent
Critical for MDR/XDR-TB treatment regimens
Technically complex due to:
Nitro heterocyclic chemistry
Prodrug activation mechanism
Strict global TB program regulation
???? Competitive success depends on:
WHO procurement compliance
Affordable global access manufacturing
Stability in tropical conditions
Combination regimen integration strategy